Format

Send to

Choose Destination
PLoS One. 2018 Oct 9;13(10):e0205277. doi: 10.1371/journal.pone.0205277. eCollection 2018.

Impact of successful treatment with direct-acting antiviral agents on health-related quality of life in chronic hepatitis C patients.

Author information

1
Department of Pharmacy, Complejo Hospitalario de Navarra, Pamplona, Spain.
2
Instituto de Salud Pública de Navarra-IdiSNA, Pamplona, Spain.
3
CIBER Epidemiología y Salud Pública (CIBERESP), Pamplona, Spain.
4
Department of Gastroenterology, Complejo Hospitalario de Navarra, Pamplona, Spain.
5
Department of Economics, Public University of Navarra, Pamplona, Spain.

Abstract

BACKGROUND:

Direct-acting antivirals (DAA) have demonstrated high efficacy to achieve sustained virological response (SVR) in chronic hepatitis C patients. We aim to assess the change in health-related quality of life (HRQoL) among patients successfully treated, and to identify predictors of this variation.

METHODS:

In a prospective observational study, patients with chronic hepatitis C who started DAA therapy between May 2016 and April 2017 completed the EQ-5D-5L questionnaire at baseline and 12 weeks after the end of therapy before knowing the virological result. Analysis included all patients with SVR.

RESULTS:

Median baseline EQ-5D-5L scores of the 206 enrolled patients were 0.857 utility and 70.0 visual analogue scale (VAS). Following SVR, a reduction occurred in the proportion of patients with mobility problems (35% vs 24%, p = 0.012), pain/discomfort (60% vs 42%, p<0.001) and anxiety/depression (57% vs 44%, p = 0.012), with an increase in utility (+0.053, p<0.001) and VAS (+10, p<0.001). Score improvements were also observed in cirrhotic (+0.048 utility, p = 0.027; +15 VAS, p<0.001) and HIV co-infected patients (+0.039 utility, p = 0.036; +5 VAS, p = 0.002). In multivariate analyses, middle age (45-64 years) and baseline anxiety/depression were associated to greater improvement in utility after SVR, and moderate-advanced liver fibrosis and cirrhosis to greater increase in VAS score. Low baseline values were associated to greater improvements in utility value and VAS score.

CONCLUSIONS:

The cure of chronic hepatitis C infection with DAA has a short term positive impact on HRQoL with improvement in mobility, pain/discomfort, anxiety/depression, utility value and VAS score. Patients with poor baseline HRQoL were the most beneficed.

Conflict of interest statement

The authors have declared that no competing interests exist.

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center